PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-08-06 (2)

Date Title Company
06-Aug-2022 U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Businesswire